




PHARMACEUTICAL 2019

Alaunos Therapeutics Inc.
Rank 97 of 363





RealRate

PHARMACEUTICAL 2019

Alaunos Therapeutics Inc. Rank 97 of 363



The relative strengths and weaknesses of Alaunos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Alaunos Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 143% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	84,285
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,483
Liabilities, Non-Current	0
Other Assets	9,669
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4.0
Other Net Income	789
Other Revenues	146
Property and Equipment	1,097
Research and Development	34,134
Selling, General and Administrative Expense	19,918

Output Variable	Value in 1000 USD
Assets	95,051
Liabilities	9,487
Expenses	54,052
Revenues	146
Stockholders Equity	85,564
Net Income	-53,117
Comprehensive Net Income	-53,117
Economic Capital Ratio	180%